Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway.
- DOI
- 10.1186/s13046-023-02818-7
- Published
- 2023 Sep 16
- Container
- Journal of experimental & clinical cancer research : CR
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13046-023-02818-7,
title = {Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway.},
author = {Peng Y and Wang Y and Tang N and Sun D and Lan Y and Yu Z and Zhao X and Feng L and Zhang B and Jin L and Yu F and Ma X and Lv C},
year = {2023},
journal = {Journal of experimental \& clinical cancer research : CR},
doi = {10.1186/s13046-023-02818-7},
url = {https://doi.org/10.1186/s13046-023-02818-7}
}RIS
TY - JOUR TI - Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. AU - Peng Y AU - Wang Y AU - Tang N AU - Sun D AU - Lan Y AU - Yu Z AU - Zhao X AU - Feng L AU - Zhang B AU - Jin L AU - Yu F AU - Ma X AU - Lv C PY - 2023 JO - Journal of experimental & clinical cancer research : CR DO - 10.1186/s13046-023-02818-7 UR - https://doi.org/10.1186/s13046-023-02818-7 ER -
APA
Y, P., Y, W., N, T., D, S., Y, L., Z, Y., X, Z., L, F., B, Z., L, J., F, Y., X, M., & C, L. (2023). Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway.. Journal of experimental & clinical cancer research : CR. https://doi.org/10.1186/s13046-023-02818-7
Source records
- pubmed · retrieved 2026-09-25T23:28:05.073Z
- europe-pmc · retrieved 2026-09-25T23:28:05.095Z
- doaj · retrieved 2026-09-25T23:28:05.092Z